In order to highlight this, we find it important to mention that in a clinical trial, in which IFNγ was targeted via an anti-IFNγ monoclonal antibody, no therapeutic impacts were produced in a cohort of non-African-American SLE patients with lupus nephritis.58 IFNγ is also of high importance for the activation of DN2 cells and, since these cells are more marked in African-American SLE patients, we consider the fact that no therapeutic impacts were observed in non-African-American patients as unsurprising and expected.13,58. This evidence concerns the gene IFNG and lupus nephritis.